Monopar Therapeutics MNPR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $3.49M-11.5% | $3.94M+52.2% | $2.59M+49.7% | $1.73M+5.3% | $1.64M-83.4% | ||
| $1.74M-21.5% | $2.21M+47.3% | $1.5M-0.1% | $1.5M-4.7% | $1.58M+37.3% | ||
| $5.23M-15.1% | $6.16M+50.4% | $4.09M+26.6% | $3.23M+0.4% | $3.22M-70.9% | ||
| $5.23M-15.1% | $6.16M+50.4% | $4.09M+26.6% | $3.23M+0.4% | $3.22M-70.9% | ||
| -$5.23M+15.1% | -$6.16M-50.4% | -$4.09M-26.6% | -$3.23M-0.4% | -$3.22M+70.9% | ||
| $1.33M+39.6% | $954.43K+45.6% | $655.47K-16.0% | $780.77K+30.8% | $596.85K+300% | ||
| -$3.89M+25.1% | -$5.2M-51.3% | -$3.44M-40.1% | -$2.45M+6.5% | -$2.62M+76.0% | ||
| -$0.46+28.1% | -$0.64-33.3% | -$0.48-37.1% | -$0.35+7.9% | -$0.38+86.2% | ||
| 8.5M+15.2% | 7.4M+4.0% | 7.1M+1.8% | 7M+0.2% | 7M+84.4% | ||
| -$3.93M+22.7% | -$5.08M-45.0% | -$3.5M-48.8% | -$2.35M+10.3% | -$2.62M+75.9% | ||
| -$190+15.9% | -$226-94.8% | -$116+96.6% | -$3.46K-379% | $1.24K— | ||
| -$32.68K-127% | $119.92K+282% | -$65.76K-164% | $102.82K+29,616% | $346-99.3% | ||
| -$5.23M+15.1% | -$6.16M-50.4% | -$4.09M-26.6% | -$3.23M-0.4% | -$3.22M+70.9% | ||
| -$5.23M+15.1% | -$6.16M-50.4% | -$4.09M-26.6% | -$3.23M-0.4% | -$3.22M+70.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Monopar Therapeutics profitable?
- Monopar Therapeutics is not currently profitable: it reported a net loss of $15.0M over the trailing twelve months.
- Where does Monopar Therapeutics's income statement data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.